Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Oligomer-beta blocker conjugates
US9782488B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9782488-B2 |
| Application number | US-53041208-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2008 |
| Priority date | Mar 12, 2007 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides water-soluble oligomer-beta blocker drug conjugates. A drug conjugate of the invention can be administered by any of a number of administration routes and exhibits properties that are different from the corresponding beta blocker not attached to the water-soluble oligomer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound according to Formula I-C: wherein: R 1 is lower alkyl; R 2 is hydrogen; R 3 is H or lower alkyl; R 4 is H or lower alkyl; R 5 is H or lower alkyl; R 6 is H or lower alkyl; R 7 is H or lower alkyl; Ar is optionally bears one or more halo, alkyl, alkoxy, or acyl substituents; and R 19 is H, halo, lower alkyl, lower alkenyl, carbamoyl, cycloalkyl, alkoxy, phenyl, substituted phenyl, amino, or heterocyclyl. 2. The compound of claim 1 , according to Formula Il: 3. The compound of claim 1 , according to Formula Im: 4. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient. 5. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form. 6. The compound of claim 1 according to any of the following structures: 7. The compound of claim 1 according to any of the following structures:
Assignees
Inventors
Classifications
Antihypertensives · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antimigraine agents · CPC title
Anxiolytics · CPC title
- A61K47/60Primary
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9782488B2 cover?
- The invention provides water-soluble oligomer-beta blocker drug conjugates. A drug conjugate of the invention can be administered by any of a number of administration routes and exhibits properties that are different from the corresponding beta blocker not attached to the water-soluble oligomer.
- Who is the assignee on this patent?
- Riggs-Sauthier Jennifer, Duarte Franco J, Nektar Therapeutics
- What technology area does this patent fall under?
- Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).